LISINOPRIL: AN INNOVATION RESPONSE TO NEW CHALLENGES OF TIME


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

There is evidence that the hydrophilic angiotensin-converting enzyme inhibitor lisinopril may be used as a first-line drug to treat elderly hypertensive patients with significant comorbidity, including this drug as part of multicomponent therapy.

全文:

受限制的访问

作者简介

N. Nikolaeva

Omsk State Medical Academy

Email: niknik.67@mail.ru
Candidate of Medical Sciences

参考

  1. Николаев Н.А. Доказательная гипертензиология: количественная оценка результата антигипертензивной терапии / М.: Издательский дом «Академия Естествознания», 2008; 92 с.
  2. Патент РФ. 2352259 (51) МПК А61В 10/00 (2006.01) Способ количественной оценки результата антигипертензивной фармакотерапии [текст] / Николаев Н.А. № 2007140850/14; заявл. 02.11.2007; опубл. 20.04.2009, бюл. №11. 8 с.: ил.
  3. Патент РФ 2362488 (51) МПК А61В 10/00 (2006.01) Способ оценки экономической эффективности результата антигипертензивной фармакотерапии [текст] / Николаев Н.А.; № 2007140839/14; заявл. 02.11.2007; опубл. 27.07.2009; бюл. № 21; 7 с. : ил.
  4. Abbound H. Growth factors and diabetic nephropathy: an overview // Kidney Int. -1997; 52 (60): 3-6.
  5. Anderson A. Role of local and systemic angiotensin in diabetic renal disease. // Kidney Int. - 1997; 63: 107-10.
  6. Bakris G., Slataper R., Vicknair N. et al. ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic patients // J. Diabetes Complications. - 1994; 8 (1): 2-6.
  7. Border W., Noble N. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis // Hypertension. - 1998; 31 (1): 181-8.
  8. Chaturvedi N., Stevenson J., Fuller J. et al. Randomised placebo controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group // Lancet. -1997; 349: 1787-92.
  9. Cohen R. Endothelial dysfunction in diabetic vascular disease // Medicographia. -1997; 19: 157-61.
  10. Cohen R. Role of nitric oxide in vasomotor regulation. In: Loscalzo J., Vitra J.A., editors. Nitric oxide and cardiovascular system / Totowa, NJ: Humana Press, 2000; pp.105-22.
  11. Cohen R. The role of nitric oxide and other endothelium derived vasoactive substances in vascular disease // Cardiovasc. Dis. - 1995; 38: 5-28.
  12. Chodoff L. Lisinopril: a new ACE inhibitor for the treatment of hypertension and congestive heart failure // Mt. Sinai. J. Med. - 1990; 57: 169-71.
  13. Egido J. Vasoactive hormones and renal sclerosis. (Perspectives in Clinical Nephrology) // Kydney Int. - 1996; 49: 578-97.
  14. Erdos E. Angiotensin I-converting enzyme and the changes in our concepts through the years // Hypertension. -1990; 16: 363-70.
  15. Kafettz K. Renal impairment in the elderly: a review / J. R. Soc. Med. - 1983; 76: 398-401.
  16. Lorenzi M., Cagliero E. Pathobiology of endothelial and other vascular cells in diabetes mellitus // Diabetes. - 1991; 40: 653-9.
  17. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker us Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // JAMA. - 2002; 288 (23): 2981-97.
  18. Nacane H., Miller F., Farasi F. et el. Gene transfer of endothelial nitric oxide synthase reduces angiotensin II-induced endothelial dysfunction // Hypertension. - 2000; 35 (2): 595-601.
  19. O’Donnel M., Rowe B., Lawson N. et а!. Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy // J. Hum. Hypertens. - 1993; 7 (4): 327-32.
  20. Parving H. Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy // J. Diabetes. Complications. - 1996; 10 (3): 133-5.
  21. Rostand S., Brown G., Kirk K. et al. Renal insufficiency in treated hypertensive patients // N. Eng. J. Med. - 1989; 320: 684-8.
  22. Walker W., Cutler J., Neuwirth R. et al. Blood pressure and renal function in the Multiple Factor Intervention Trial (MRFIT) // J. Hypertens. - 1990; 8 (3): 3.
  23. Vallejo S., Angulo J., Peiro C. et ак Highly glycated oxyhaemoglobin impairs nitric oxide relaxations in human mesenteric microvessels // Diabetologia. - 2000; 43: 83-90.
  24. Wattanapitayakul S., Weinstein D., Holycross B., Bauer J. Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders // FASEB J. - 2000; 14 (2): 271-8.
  25. Williams S., Goldfine A., Timimi F. et al. Acute hyperglycemia attenuates endothelium-dependent vasodilatation in humans in vivo // Circulation. -1998; 97: 1695-701.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2013
##common.cookie##